Deepening a Simple Question: Can MSCs Be Used to Treat Cancer?

Gomes, Janaina F.; Assoni, Amanda F.; Pelatti, Mayra; Coatti, Giuliana Castello; Okamoto, Oswaldo Keith; Zatz, Mayana

doi:10.21873/anticanres.11881

Cited by 12 publications

(11 citation statements)

References 157 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They include cancer vaccines, monoclonal antibodies, and cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy [ 5 ]. Because of their enhanced tumor targeting and minimal off-target effects stem cell therapy is gaining ground and is becoming a popular choice for treatment against cancer [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Decidua Parietalis Mesenchymal Stem/Stromal Cells and Their Secretome Diminish the Oncogenic Properties of MDA231 Cells In Vitro

Basmaeil

Bahattab

Subayyil

et al. 2021

Cells

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have been shown to suppress tumor growth, inhibit angiogenesis, regulate cellular signaling, and induce apoptosis in cancer cells. We have earlier reported that placenta-derived decidua parietalis mesenchymal stem/stromal cells (DPMSCs) not only retained their functional characteristics in the cancer microenvironment but also exhibited increased expression of anti-apoptotic genes, demonstrating their anti-tumor properties in the tumor setting. In this study, we have further evaluated the effects of DPMSCs on the functional outcome of human breast cancer cell line MDA231. MDA231 cells were exposed to DPMSCs, and their biological functions, including adhesion, proliferation, migration, and invasion, were evaluated. In addition, genomic and proteomic modifications of the MDA231 cell line, in response to the DPMSCs, were also evaluated. MDA231 cells exhibited a significant reduction in proliferation, migration, and invasion potential after their treatment with DPMSCs. Furthermore, DPMSC treatment diminished the angiogenic potential of MDA231 cells. DPMSC treatment modulated the expression of various pro-apoptotic as well as oncogenes in MDA231 cells. The properties of DPMSCs to inhibit the invasive characteristics of MDA231 cells demonstrate that they may be a useful candidate in a stem-cell-based therapy against cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Decidua Parietalis Mesenchymal Stem/Stromal Cells and Their Secretome Diminish the Oncogenic Properties of MDA231 Cells In Vitro

Basmaeil

Bahattab

Subayyil

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Mounting evidence suggests a key role of MSCs in MET via the secretion of the hepatocyte growth factor, which has been associated with an aggressive phenotype and poor clinical prognosis in several types of solid tumors [17,18]. Last, since MSCs are being considered the most promising stem cell type for future regenerative medicine therapies [19], the revealed potential of altered MSCs to contribute to malignancies is of great concern and a limiting factor for otherwise efficient regenerative therapies [20,21]. The key question in this regard is therefore whether low-dose rate radiation exposures are capable of producing changes in the MSCs that can cause the transformation of stem cells into CSCs [22].…”

Section: Introductionmentioning

confidence: 99%

Formation of γH2AX and pATM Foci in Human Mesenchymal Stem Cells Exposed to Low Dose-Rate Gamma-Radiation

Ul'yanenko

Pustovalova

Koryakin

et al. 2019

IJMS

View full text Add to dashboard Cite

DNA double-strand breaks (DSB) are among the most harmful DNA lesions induced by ionizing radiation (IR). Although the induction and repair of radiation-induced DSB is well studied for acute irradiation, responses to DSB produced by chronic IR exposures are poorly understood, especially in human stem cells. The aim of this study was to examine the formation of DSB markers (γH2AX and phosphorylated kinase ATM, pATM, foci) in human mesenchymal stem cells (MSCs) exposed to chronic gamma-radiation (0.1 mGy/min) in comparison with acute irradiation (30 mGy/min) at cumulative doses of 30, 100, 160, 240 and 300 mGy. A linear dose-dependent increase in the number of both γH2AX and pATM foci, as well as co-localized γH2AX/pATM foci (“true” DSB), were observed after an acute radiation exposure. In contrast, the response of MSCs to a chronic low dose-rate IR exposure deviated from linearity towards a threshold model, for γH2AX, pATM foci and γH2AX/pATM foci, with an indication of a “plateau”. The state of equilibrium between newly formed DSB at a low rate during the protracted exposure time and the elimination of a fraction of DSB is proposed as a mechanistic explanation of the non-linear DSB responses following a low dose-rate irradiation. This notion is supported by the observation of the elimination of a substantial fraction of DSB 6 h after the cessation of the exposures. Our results demonstrate non-linear dose responses for γH2AX and pATM foci in human MSCs exposed to low dose-rate IR and showed the existence of a threshold, which may have implications for radiation protection in humans.

show abstract

“…They are pluripotent stromal cells, which can differentiate into a variety of cell types, including osteoblasts, myocytes, and adipocytes, and are easy to obtain from many tissues [ 17 ]. MSCs are proposed to own therapeutic functions serving as agent carriers to deliver tumor targeting drug to OC cells [ 18 , 19 ]. Studies have reported that MSCs have the potential to treat various diseases, such as cancer [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance

2022

View full text Add to dashboard Cite

Objective Ovarian cancer (OC) is a major threat to women’s health. Mesenchymal stem cells (MSCs) are key regulators in cellular communication by secreting extracellular vesicles (EVs) that are involved in OC. This study probed into the mechanism of human MSCs derived-EVs (hMSC-EVs) in regulating OC cell growth and chemotherapy resistance. Methods hMSCs and EVs were isolated and identified. After adding EVs, the uptake of EVs by OC CAOV3/ES2 cells (for in vitro studies), and cell proliferation, migration, and invasion were detected. Downregulated miRNAs in hMSC-EVs were screened and miR-18a-5p expression in OC patients was detected. The prognosis of OC patients was analyzed. Binding sites of miR-18a-5p and NACC1 were predicted and validated. NACC1 expression in OC tissues was measured by RT-qPCR, and its correlation with miR-18a-5p was analyzed by Pearson method. AKT/mTOR pathway activation was assessed by WB. The cisplatin sensitivity of EVs-treated CAOV3 cells was evaluated via MTT assay and tested by tumor formation assay in nude mice. Results hMSC-EVs suppressed OC cell proliferation, migration, and invasion. miR-18a-5p was downregulated in OC and miR-18a-5p low expression was associated with a poor prognosis. EV-encapsulated miR-18a-5p targeted NACC1. NACC1 was upregulated in OC tissues. miR-18a-5p knockdown and NACC1 overexpression both annulled the inhibition of hMSC-EVs on OC cell growth. AKT and mTOR were elevated in OC and NACC1 activated the AKT/mTOR pathway in OC cells. hMSC-EVs promoted cisplatin sensitivity of OC cells by carrying miR-18a-5p. Conclusion hMSC-EVs-derived miR-18a-5p inhibits OC cell proliferation, migration, invasion, and chemotherapy resistance.

show abstract

Deepening a Simple Question: Can MSCs Be Used to Treat Cancer?

Cited by 12 publications

References 157 publications

Decidua Parietalis Mesenchymal Stem/Stromal Cells and Their Secretome Diminish the Oncogenic Properties of MDA231 Cells In Vitro

Decidua Parietalis Mesenchymal Stem/Stromal Cells and Their Secretome Diminish the Oncogenic Properties of MDA231 Cells In Vitro

Formation of γH2AX and pATM Foci in Human Mesenchymal Stem Cells Exposed to Low Dose-Rate Gamma-Radiation

miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance

Contact Info

Product

Resources

About